Literature DB >> 28303906

Advances and challenges in targeting FGFR signalling in cancer.

Irina S Babina1, Nicholas C Turner1,2.   

Abstract

Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes. Deregulation of FGFR signalling is observed in a subset of many cancers, making activated FGFRs a highly promising potential therapeutic target supported by multiple preclinical studies. However, early-phase clinical trials have produced mixed results with FGFR-targeted cancer therapies, revealing substantial complexity to targeting aberrant FGFR signalling. In this Review, we discuss the increasing understanding of the differences between diverse mechanisms of oncogenic activation of FGFR, and the factors that determine response and resistance to FGFR targeting.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28303906     DOI： 10.1038/nrc.2017.8

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  203 in total

Review 1.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 2.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

3.  TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.

Authors:  Lipika Goyal; Lei Shi; Leah Y Liu; Ferran Fece de la Cruz; Jochen K Lennerz; Srivatsan Raghavan; Ignaty Leschiner; Liudmila Elagina; Giulia Siravegna; Raymond W S Ng; Phuong Vu; Krushna C Patra; Supriya K Saha; Raul N Uppot; Ron Arellano; Stephanie Reyes; Takeshi Sagara; Sachie Otsuki; Brandon Nadres; Heather A Shahzade; Ipsita Dey-Guha; Isobel J Fetter; Islam Baiev; Emily E Van Seventer; Janet E Murphy; Cristina R Ferrone; Kenneth K Tanabe; Vikram Deshpande; James J Harding; Rona Yaeger; Robin K Kelley; Alberto Bardelli; A John Iafrate; William C Hahn; Cyril H Benes; David T Ting; Hiroshi Hirai; Gad Getz; Dejan Juric; Andrew X Zhu; Ryan B Corcoran; Nabeel Bardeesy
Journal:  Cancer Discov       Date:  2019-05-20       Impact factor: 39.397

4.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

Review 5.  Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.

Authors:  Volker M Lauschke; Lili Milani; Magnus Ingelman-Sundberg
Journal:  AAPS J       Date:  2017-11-27       Impact factor: 4.009

6.  FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.

Authors:  Joshua Z Drago; Luigi Formisano; Carlos L Arteaga; Aditya Bardia; Dejan Juric; Andrzej Niemierko; Alberto Servetto; Seth A Wander; Laura M Spring; Neelima Vidula; Jerry Younger; Jeffrey Peppercorn; Megan Yuen; Giuliana Malvarosa; Dennis Sgroi; Steven J Isakoff; Beverly Moy; Leif W Ellisen; A John Iafrate
Journal:  Clin Cancer Res       Date:  2019-08-01       Impact factor: 12.531

7.  Inhibition of FGF Receptor-1 Suppresses Alcohol Consumption: Role of PI3 Kinase Signaling in Dorsomedial Striatum.

Authors:  Oren Even-Chen; Segev Barak
Journal:  J Neurosci       Date:  2019-08-02       Impact factor: 6.167

8.  C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis.

Authors:  Zhuo Chen; Lin-Jiang Tong; Bai-You Tang; Hong-Yan Liu; Xin Wang; Tao Zhang; Xian-Wen Cao; Yi Chen; Hong-Lin Li; Xu-Hong Qian; Yu-Fang Xu; Hua Xie; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2018-11-28       Impact factor: 6.150

9.  SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models.

Authors:  Xi-Fei Jiang; Yang Dai; Xia Peng; Yan-Yan Shen; Yi Su; Man-Man Wei; Wei-Ren Liu; Zhen-Bin Ding; Ao Zhang; Ying-Hong Shi; Jing Ai
Journal:  Acta Pharmacol Sin       Date:  2017-09-14       Impact factor: 6.150

10.  FGFR2 regulation by picrasidine Q inhibits the cell growth and induces apoptosis in esophageal squamous cell carcinoma.

Authors:  Yuanyuan Shi; Xuejiao Liu; Mangaladoss Fredimoses; Mengqiu Song; Hanyong Chen; Kangdong Liu; Mee-Hyun Lee; Zigang Dong
Journal:  J Cell Biochem       Date:  2017-10-27       Impact factor: 4.429
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.